Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain

Change in Dysmenorrhea (DYS), According to Patient Reported NRS

Participants rated the change in DYS using an NRS.

Time frame: Baseline (Month 0) through Month 24

Change in Non-Menstrual Pelvic Pain (NMPP), According to Patient Reported NRS

Participants rated the change in NMPP using an NRS.

Time frame: Baseline (Month 0) through Month 24

Change in Dyspareunia, According to Patient Reported NRS

Participants rated the change in Dyspareunia using an NRS.

Time frame: Baseline (Month 0) through Month 24

Change in Level of Endometriosis Pain-through Patient Global Impression of Change (PGIC)

Participants will evaluate the change in their endometriosis-related pain since initiation of study drug, using the Patient Global Impression of Change (PGIC) questionnaire.

Time frame: Baseline (Month 0) through Month 24

Change in Quality of Life (QoL) through Endometriosis Health Profile-30 (EHP-30)

The EHP-30 is a disease-specific self-administered questionnaire used to measure health related QoL in women with endometriosis.

Time frame: Baseline (Month 0) through Month 24

Change in Treatment Satisfaction Though PGIC

Participants will evaluate the change in treatment satisfaction through PGIC questionnaire.

Time frame: Baseline (Month 0) through Month 24

Change in Treatment Satisfaction Though Clinician Global Impression of Change (CGIC)

The CGIC scale requiring the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention.

Time frame: Baseline (Month 0) through Month 24

Change in Work Productivity- through Work Productivity and Activity Impairment Questionnaire

The Work Productivity and Activity Impairment Questionnaire is used to measure the effect of general health and symptom severity on work productivity and regular activities during the past seven days.

Time frame: Baseline (Month 0) through Month 24

Change in Healthcare Resource Utilization Questionnaire (HCRU) Associated with Endometriosis Through HCRU Questionnaire

The HCRU will record the use of health resources (emergency room, physician visit, hospitalization, etc.) prior to and during the study.

Time frame: Baseline (Month 0) through Month 24

Evaluation of Elagolix Dosing

Elagolix dosing will be summarized by clinical diagnosis using descriptive statistics including mean, standard deviation, median, quartiles, minimum and maximum and 95% Confidence Interval (CI) for the mean.

Time frame: Baseline (Month 0) through Month 24

Percentage of Participants Who Change Dose of Elagolix

Percentage of participants who change dose of elagolix.

Time frame: Baseline (Month 0) through Month 24

Reason Participants Change Dose of Elagolix

Reason participants change dose of elagolix.

Time frame: Baseline (Month 0) through Month 24

Percentage of Participants Using Other Treatments of Endometriosis

Percentage of participants using other medications or procedures for the treatment of endometriosis.

Time frame: Baseline (Month 0) through Month 24

Percentage of Participants Using Pain/Rescue Medications

Percentage of participants using pain/rescue medications.

Time frame: Baseline (Month 0) through Month 24

Percentage of Participants Using Physiotherapy/Cognitive-Behavioral Therapy (Physio/CBT) During and Before the Course of this Observation Period

Percentage of participants using physio/CBT during and before the course of this observation period.

Time frame: Baseline (Month 0) through Month 24

Reason for Change at Subsequent Visits in Physiotherapy/Cognitive-Behavioral Therapy (Physio/CBT) During and Before the Course of this Observation Period

Reason for change at subsequent visits in physio/CBT during and before the course of this observation period.

Time frame: Baseline (Month 0) through Month 24

Percentage of Participants Using Surgical Intervention During and Before the Course of this Observation Period

Percentage of participants using surgical intervention during and before the course of this observation period.

Time frame: Baseline (Month 0) through Month 24

Percentage of Participants Using Add Back

Percentage of participants using add back.

Time frame: Baseline (Month 0) through Month 24

Percentage of Participants Using Concomitant Medications

Percentage of participants using concomitant medications.

Time frame: Baseline (Month 0) through Month 24

Number of Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment.

Time frame: Baseline (Month 0) through Month 24